Iovance Stock Hits 52-Week High After 50% Trial Response, UBS Raises Target
Shares climbed over 14% to a 52-week high after Iovance reported a 50% response rate in its pilot lifileucel trial for soft-tissue sarcomas and UBS lifted its price target from $2 to $4. Q4 revenue rose 17.7% to $86.8M and AMTAGVI sales jumped 112% to $264M.
1. Clinical Trial Success Spurs Registrational Plan
Iovance’s pilot study for lifileucel monotherapy in advanced soft-tissue sarcomas achieved a 50% confirmed objective response rate among the first six evaluable patients. The company plans to launch a single-arm registrational trial in Q2 2026 and pursue FDA expedited approval while exploring additional high-grade sarcoma subtypes, targeting over 8,000 annual cases in the US and Europe.
2. Solid Q4 Revenue Growth and AMTAGVI Uptake
In fiscal Q4 2025, Iovance generated $86.77 million in revenue, up 17.7% year-over-year and exceeding consensus by $5.76 million, with EPS of negative $0.18 in line with estimates. Full-year AMTAGVI product revenue reached $264 million, a 112% increase driven by accelerated uptake at academic and community treatment centers, with fiscal 2026 guidance forthcoming.
3. Technical Strength and Analyst Upgrades
Shares jumped 14.5% to a new 52-week high, trading nearly 60% above their 20-day SMA and nearing overbought RSI levels. Short interest remains elevated at 39.6%, while UBS raised its price target to $4 with a Neutral rating and other brokers increased targets to $5 and $11, signaling mixed near-term outlook.